Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.
Ir J Med Sci
; 191(2): 919-920, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1160656
ABSTRACT
INTRODUCTION:
Based on the severity of thrombocytopenia, patients with immune thrombocytopenic purpura (ITP) are at an increased risk of mucocutaneous or major bleeding.DISCUSSION:
There has been an increased risk of ITP after administration of various vaccines like influenza, measles-mumps-rubella, hepatitis B, and diphtheria-tetanus-pertussis. The pathogenesis of vaccine-related thrombocytopenia is not completely clear and is probably caused by molecular mimicry. Till date, there have been few reported cases of thrombocytopenia in the pharmacovigilance databases after patients received the Pfizer and Moderna coronavirus disease-19 (COVID-19) vaccines.CONCLUSION:
Emergency physicians should be aware of the occurrence of vaccine-induced ITP in patients who present with bleeding manifestations, especially after the current boost in COVID-19 vaccination drive worldwide.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19
/
Measles
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Ir J Med Sci
Year:
2022
Document Type:
Article
Affiliation country:
S11845-021-02614-2
Similar
MEDLINE
...
LILACS
LIS